Erlotinib in the treatment of non-small cell lung cancer

References

• Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 899–901 (1995).
   PubMed Web of Science ®Google Scholar
• Kelly KK, Crowley J, Bunn PA et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19, 3210–3218 (2001).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani C et al. Comparison of four different regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Arteaga C. Epidermal growth factor receptor in human tumors: more than just expression? Oncologist 7(S14), 31–39 (2002).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor tyrosine kinase. Cancer Res. 57(21), 4838–4848 (1997).
   PubMed Web of Science ®Google Scholar
• Pollack V, Savage D, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effect in athymic mice. J. Pharmacol. Exp. Ther. 291, 739–748 (1999).
   PubMed Web of Science ®Google Scholar
• Desai B, Higgins B, Smith M et al. Antitumor activity of the EGFR/TK inhibitor TarcevaTM (erlotinib, OSI-774) in tumor models. Eur. J. Cancer 38, 63 (2002) (Abstract 203).
   Google Scholar
• Elsayed Y, Sausville E. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 6(6), 517–537 (2001).
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Huang S, Armstrong E et al. Modulation of radiation response after HER1/EGFR inhibition by erlotinib (TarcevaTM) in lung and head and neck carcinoma. Lung Cancer 41(Suppl. 2), S72 (2003).
   Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19(13), 3267–3279 (2001).
   PubMed Web of Science ®Google Scholar
• Karp D, Silberman R, Csudae R et al. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 18, 388a (1999) (Abstract 1499).
   Google Scholar
• Mita A, Forouzesh B, Hidalgo M et al. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 (Erlotinib or Tarceva) in combination with docetaxel. Eur. J. Cancer 38, S53 (2002).
   Google Scholar
• Mita M, Patnaik A, Hammond L et al. Phase I, pharmacokinetic (PK) and biologic study of erlotinib (OSI-774) in combination with paclitaxel and carboplatin in advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. 22, 209 (2003) (Abstract 837).
   Google Scholar
• Ratain M, George C, Janisch L et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 76b (Abstract 2115) (2002).
   Google Scholar
• Pérez-Soler R, Chachoua A, Hammond L et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol. 22(16), 3238–3247 (2004).
   PubMed Web of Science ®Google Scholar
• Patel JD, Miller VA, Kris MG et al. Encouraging activity and durable responses demonstrated by the EGFR tyrosine kinase inhibitor erlotinib (Tarceva TM, OSI-774) in patients with advanced bronchioalveolar (BAC) cell carcinoma. Lung Cancer 41, S56 (2003).
   Google Scholar
• Miller V, Patel N, Shah N et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): Preliminary results of a Phase II trial. Proc. Am. Soc. Clin. Oncol. 22, 619 (2003) (Abstract 2491) .
   Google Scholar
• Kris M, Sandler A, Miller V et al. Cigarette smoking history predicts sensitivity to erlotinib: Results of a Phase II trial in patients with bronchioloalveolar carcinoma (BAC). Proc. Am. Soc. Clin. Oncol. 23, 628 (2004) (Abstract 7062).
   Google Scholar
• Sandler A, Minniberg E, Henderson T et al. A Phase I/II study of the antiVEGF Mab bevacizumab (AvastinTM) and erlotinib (TarcevaTM), a HER1/EGFR-TK Inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer. Lung Cancer 41, S36 (2003).
   Google Scholar
• Sandler A, Blumenschein G, Henderson T et al. A Phase I/II trial evaluating the antiVEGF Mab bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor for patients with recurrent non-small lung cancer. Proc. Am. Soc. Clin. Oncol. 23, 127 (2004) (Abstract 2000).
   Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna E et al. Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 23, 617 (2004) (Abstract 7010).
   Google Scholar
• Herbst R, Prager D, Hermann R et al. TRIBUTE - A Phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 23, (2004) (Abstract 7011).
   Google Scholar
• Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 22, 777–784 (2002).
   Google Scholar
• Herbst RS, Giaconne G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 22, 785–794 (2002).
   Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 21, 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 290, 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Specific activating mutations of the epidermal growth factor and responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350 (21), 2129–2139 (2004).
   PubMedGoogle Scholar
• Paez J, Janne P, Lee J et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497 (2004).
   PubMed Web of Science ®Google Scholar
• Yang SH, Mechanic LE, Yang P et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res. 11(6), 2106–2110 (2005).
   PubMed Web of Science ®Google Scholar
• Marchetti A, Martella C, Felicioni L et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23(4), 857–865 (2005).
   PubMed Web of Science ®Google Scholar
• Han SW, Kim TY, Hwang PG et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23(11), 2493–2501 (2005).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23(11), 2513–2520 (2005).
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339–346 (2005).
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Endoh H, Kuwano et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64(24), 8919–8923 (2005).
   Google Scholar
• Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133–144 (2005).
   PubMed Web of Science ®Google Scholar
• Mass RD, Press M, Anderson S et al. Improved survival benefit from Herceptin (Trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc. Am. Soc. Clin. Oncol. 20 (2001) (Abstract 85).
   Google Scholar
• Gatzemeier U, Groth G, Butts C et al. Randomized Phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. 15, 19–27 (2004).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97(9), 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Franklin W, Chansky K, Gumerlock P et al. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). Proc. Am. Soc. Clin. Oncol. 23 (2004) (Abstract 7123).
   Google Scholar
• Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1), e17 (2005).
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 17(Suppl. 12), 23–28 (2003).
   PubMedGoogle Scholar
• Johnson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer 41, S23–29 (2003).
   Google Scholar
• Lonardo F, Dragnev KH, Freemantle SJ et al. Evidence for the epidermal growth factor receptor as target for lung cancer prevention. Clin. Cancer Res. 8, 54–60 (2002).
   PubMed Web of Science ®Google Scholar
• Wakeling AE. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol. 2(4), 382–387 (2002).
   PubMedGoogle Scholar
• Torrance CJ, Jackson PE, Montgomery E et al. Combinational chemoprevention for intestinal neoplasia. Nature Med. 6, 1024–1028 (2000).
   PubMed Web of Science ®Google Scholar